EXACT SCIENCES

Stanley Lapidus founded Exact Sciences in 1995 with the vision of detecting cancer from body fluids rather than invasive procedures. The company struggled for years — early DNA-based stool tests had poor sensitivity.

The breakthrough came when Kevin Conroy became CEO in 2009 and focused entirely on developing Cologuard, a multi-target stool DNA test for colorectal cancer. Cologuard received FDA approval in 2014 and was included in the US Preventive Services Task Force screening guidelines — the gold standard for insurance coverage.

The TV ad campaigns ("Cologuard — the noninvasive way to screen for colon cancer") made it a household name.

Cancer screening and diagnostics company. Exact Sciences' flagship product, Cologuard, is an at-home colon cancer screening test — patients mail a stool sample to the lab and get results without ever getting a colonoscopy.

Revenue comes from test sales (Cologuard costs approximately $600, covered by most insurance), oncology diagnostics (through the Genomic Health acquisition), and emerging multi-cancer screening tests. Annual revenue exceeds $2.5 billion.

Cologuard (at-home stool DNA test for colorectal cancer screening — 10+ million tests completed), Cologuard Plus (next-generation version with improved accuracy), Oncotype DX (genomic tests predicting breast and colon cancer recurrence — acquired via Genomic Health), and multi-cancer early detection tests (in development). The Oncotype DX test helps doctors decide whether cancer patients need chemotherapy.

Multi-cancer early detection. Exact Sciences is developing a blood-based test that screens for multiple cancers simultaneously — the holy grail of cancer diagnostics.

If successful, a single blood draw could detect dozens of cancer types at early, treatable stages. The Cologuard Plus (next-gen version with better sensitivity and specificity) aims to address physician concerns.

International expansion brings Cologuard to markets where colonoscopy infrastructure is limited.

Colonoscopy is the gold standard. Gastroenterologists have resisted Cologuard, arguing that colonoscopy is more accurate and can remove precancerous polyps during the procedure (Cologuard cannot).

The false positive rate (~13%) means some patients get unnecessary follow-up colonoscopies. Competition from blood-based cancer screening tests (Grail/Galleri, Guardant Health) could disrupt Cologuard's position.

The company also paid $2.8 billion for Genomic Health in 2019, creating integration challenges.

No major VC funding — Exact Sciences went public in 2001 and has funded growth through public markets. Key shareholders include Vanguard, BlackRock, and Baillie Gifford.